Abstract:Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over age 65 in industrialized nations. The exudative AMD accounts for only 10% to 20% of AMD cases, but causes 80 to 90% of cases with severe vision loss related to AMD. The current intravitreal injection of anti-VEGF (vascular endothelial growth factor) therapies using Avastin or Lucentis has several unmet clinical needs, such as to minimize the frequency of injection, to decrease the systemic side effects, and to evaluate the effect of therapies. We propose to develop a drug delivery system that could perform sustained release of anti-VEGF drug by multifunctional drug-loaded microparticles (MPs). A modified double emulsion technique has firstly been used to fabricate biodegradable poly-lactic-co-glycolic acid (PLGA) MPs. The MPs could provide fluorescence, ultrasound, and OCT contrast simultaneously. Meanwhile, linear correlations has been observed between fluorescence intensity and MPs concentration, same as ultrasound intensity and MPs concentration. One of the anti-VEGF drugs (Avastin) has been conjugated to MPs to increase binding efficiency for target delivery. However, the modified double emulsion process is not suitable for encapsulating fragile protein drugs, such as Lucentis. The electrospray process has been introduced to overcome the limitations of the double emulsion process. Both monolayer MPs and double-layer MPs with core-shell structure are fabricated by single-axial and co-axial electrospray, respectively. To optimize the fabrication process, the effects of the applied voltage and the flow rate on the resulting and co-axial jet and the MPs size has been investigated. The results indicate that both the average size of MPs and the diameter of the co-axial jet increased as the flow rate increasing and decreased as the applied voltage increasing. A theoretical model using instability analysis has been developed to understand the process physics and predict the process outcome. Meanwhile, the biodegradation time of PLGA MPs as well as the bioavailability of Lucentis under single-axial electrospray is tested by enzyme-linked immunosorbent assay (Elisa). After the MPs fabrication and characterization, the inflammation experiment on intravitreal injection of MPs has been investigated by immunocytochemical analysis on in vivo chick model. CD45, Islet1, and Draq5 are used to label microglia, horizontal cells, and the nuclear DNA, respectively. TUNEL and CC3 are selected as cell death model to further investigate the cell apoptosis after injection. The results show that MP injection at a dose of 20??g and below does not cause inflammation under our experimental condition. However, significant microglia reactive as well as cell death (labeled by TUNEL) provided the evidence that MPs at a dose of 200??g and above induces significant retinal inflammation and cell death.

Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization

Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration

A Bioengineered Anti‐vegf Protein with High Affinity and High Concentration for Intravitreal Treatment of Wet Age‐related Macular Degeneration

Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Author Response for "polymorphic Nanobody Crystals As Long‐acting Intravitreal Therapy for Wet Age‐related Macular Degeneration"

Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration

A Non-immunogenic Bivalent d -Protein Potently Inhibits Retinal Vascularization and Tumor Growth

Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy

A peptidic network antibody inhibits both angiogenesis and inflammatory response

Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo

Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis

1407 Expanding the Therapeutic Index of MMAE-based Antibody-Drug Conjugates (adcs) with a Novel Linker System (LD343)

Drug Loaded Multifunctional Microparticles for Anti-VEGF Therapy of Exudative Age-related Macular Degeneration

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

An antibody-like peptidic network for anti-angiogenesis

A Monotargeting Peptidic Network Antibody Inhibits More Receptors for Anti-Angiogenesis

Injectable Anti‐inflammatory Supramolecular Nanofiber Hydrogel to Promote Anti‐VEGF Therapy in Age‐Related Macular Degeneration Treatment

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates